Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 19/20 | 0.50 |
| ▸ | USP2 | O75604 | 11/20 | 0.50 |
| ▸ | TSHR | P16473 | 6/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 14/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 6/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17281968 | 0.92 | CYP2D6 (0.44) | CYP3A4USP2TSHRCYP2C19CYP2D6 | |
| SCHEMBL25849299 | 0.89 | CYP3A4 (0.45) | CYP3A4USP2TSHRCYP2C19CYP2D6 | |
| SCHEMBL18926696 | 0.84 | CYP3A4 (0.56) | CYP3A4USP2TSHRCYP2C19CYP2D6 | |
| SCHEMBL24926380 | 0.84 | CYP3A4 (0.40) | CYP3A4USP2TSHRCYP2C19CYP2D6 | |
| SCHEMBL13400770 | 0.84 | CYP3A4 (0.55) | CYP3A4USP2TSHRCYP2C19CYP2D6 | |
| SCHEMBL27281828 | 0.84 | CYP3A4 (0.55) | CYP3A4USP2TSHRCYP2C19CYP2D6 | |
| SCHEMBL13400806 | 0.83 | CYP3A4 (0.54) | CYP3A4USP2TSHRCYP2C19CYP2D6 | |
| SCHEMBL20706272 | 0.81 | TSHR (0.41) | CYP3A4USP2TSHRCYP2C19CYP2D6 | |
| SCHEMBL21934376 | 0.81 | CYP2D6 (0.47) | CYP3A4USP2TSHRCYP2C19CYP2D6 | |
| SCHEMBL24411695 | 0.81 | CYP2D6 (0.54) | CYP3A4USP2TSHRCYP2C19CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230029378-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY | NURIX THERAPEUTICS, INC. | 2023-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230029378-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY | CBL, XIAP, BTK | CYP3A4 4366/4885USP2 22/4885TSHR 4040/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.